These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 8062938

  • 1. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
    Blumenfeld Z, Lang N, Amit A, Kahana L, Yoffe N.
    Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
    [Abstract] [Full Text] [Related]

  • 2. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, Caruso A, Mancuso S.
    Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 4. [Application of gonadotropin-releasing hormone agonist for triggering ovulation in high risk gonadotropin stimulating cycles of infertile polycystic ovary syndrome patients].
    Dong H, Chen S, Xing F.
    Zhonghua Fu Chan Ke Za Zhi; 1999 Feb 01; 34(2):94-6. PubMed ID: 11263206
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC.
    Hum Reprod; 2013 Jul 01; 28(7):1929-42. PubMed ID: 23624582
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea.
    Martin KA, Hall JE, Adams JM, Crowley WF.
    J Clin Endocrinol Metab; 1993 Jul 01; 77(1):125-9. PubMed ID: 8325934
    [Abstract] [Full Text] [Related]

  • 11. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb 01; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 12. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
    Kuroda G.
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar 20; 63(3):247-59. PubMed ID: 3111899
    [Abstract] [Full Text] [Related]

  • 13. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 20; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 14. Clomiphene citrate-resistant polycystic ovary syndrome. Preventing multifollicular development.
    Ergür AR, Yergök YZ, Ertekin A, Küçük T, Müngen E, Tütüncü L.
    J Reprod Med; 1998 Mar 20; 43(3):185-90. PubMed ID: 9564642
    [Abstract] [Full Text] [Related]

  • 15. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.
    Hum Reprod; 2006 May 20; 21(5):1260-5. PubMed ID: 16439507
    [Abstract] [Full Text] [Related]

  • 16. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH.
    Hum Reprod; 2013 Sep 20; 28(9):2522-8. PubMed ID: 23633553
    [Abstract] [Full Text] [Related]

  • 17. Serum 17beta-estradiol. Index of follicular maturation during gonadotropin therapy.
    Notation AD, Tagatz GE, Steffes MW.
    Obstet Gynecol; 1978 Feb 20; 51(2):204-9. PubMed ID: 622235
    [Abstract] [Full Text] [Related]

  • 18. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan 20; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 19. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA, Sibai H, Mostafa MI, Gibreel A, Darwish E, Maghraby H.
    Hum Reprod; 2018 Jun 01; 33(6):1079-1086. PubMed ID: 29562260
    [Abstract] [Full Text] [Related]

  • 20. A modified hMG-GnRH method for the induction of ovulation in infertile women with severe hypogonadotropic amenorrhea.
    Yokoi N, Uemura T, Murase M, Kondoh Y, Ishikawa M, Hirahara F.
    Endocr J; 2002 Apr 01; 49(2):159-64. PubMed ID: 12081234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.